IPO Details
Bidding Dates
10 Feb 25 - 12 Feb 25
Price Range ₹
151 - 159
Total Equity
₹ 77.96Cr
Lot Size
800
Exchange Status
NSE
IPO Doc
Subscription Rate
Non-Institutional Investor
0.00×
Qualified Institutional Buyers
0.00×
Employees
0.00×
Retail Investors
0.00×
Total subscription Rate
0.00×
IPO Timeline
Offer start
10 Feb 2025
Offer end
12 Feb 2025
Allotment
13 Feb 2025
Refund initiation
14 Feb 2025
Demat transfer
14 Feb 2025
Listing
17 Feb 2025
Offer start
10 Feb 2025
Offer end
12 Feb 2025
Allotment
13 Feb 2025
Refund initiation
14 Feb 2025
Demat transfer
14 Feb 2025
Listing
17 Feb 2025
About Company
Chandan Healthcare Limited, established in September 2003, operates diagnostic centers across North India, offering both pathology and radiology testing services. As of December 31, 2024, the company manages one flagship laboratory, seven central laboratories, and twenty-six satellite centers, along with a network of over three hundred collection centers spanning more than 23 cities in Uttar Pradesh and over 19 in Uttarakhand. The company provides a comprehensive range of 1,496 diagnostic tests, including: - 481 routine pathology tests covering basic biochemistry and hematology, along with 1,015 specialized tests such as immunohistopathology and molecular pathology. - 545 radiology tests, including X-rays, ultrasonography, CT scans, MRI, and advanced CT imaging. Its radiology facilities are equipped with eleven CT scanners and four MRI machines. As of December 31, 2024, the company employs 15 radiologists, 23 pathologists, and over 161 other qualified healthcare professionals. Products and Services: - Routine pathology tests - Specialized pathology tests - Radiology diagnostics - Preventive and wellness services - Home collection services Additionally, the company sells medical consumables such as X-ray films and reagents. Its subsidiary, Chandan Pharmacy Limited, operates medical stores that offer a variety of pharmaceutical products.
Year Founded
03-09-2003
Promotor Details
Amar Singh
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 69.93 | 49.2 |
| Share Capital | 13985820 | 12030884 |
Offer to Public
49,03,200.00 Cr
Project Details
- None - Nonecr
Highlights
- The company has an extensive presence across North India, ensuring accessibility and market coverage.
- Accredited by NABL and NABH, guaranteeing reliable and accurate diagnostic services.
- A well-established footprint in the region, contributing significantly to overall revenue.
- Generates income from B2B, B2G, and B2C segments, reducing dependency on a single market.
- Enhances operational efficiency and expands market reach through strategically located laboratories and collection centers.
Challenges
- A significant reliance on the Uttar Pradesh market makes the company vulnerable to local economic fluctuations and policy changes.
- Changes in healthcare regulations could lead to higher compliance costs and operational challenges.
- Operating a large number of facilities requires substantial investment, which could impact profitability and financial stability.
- Potential legal disputes and regulatory hurdles may affect business operations and financial performance.
- Advancements in diagnostic technology require ongoing investment to stay competitive, increasing operational costs.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2023 | 9,813.48 | 2,000.00 | 358.63 | 336.81 | 1.6841 |
| 2024 | 12,917.37 | 2,000.00 | 358.63 | 336.81 | 1.6841 |
| 2022 | 8,153.74 | 2,000.00 | -109.25 | -317.56 | -1.5878 |
